A reactive intermediate generated by lipid peroxidation, 4-hydroxy-2-nonenal (HNE), has received considerable attention as a potential effector of oxidative damage and A␤ peptide-mediated neurotoxicity in Alzheimer disease (AD). However, little is known about aldo-keto oxidoreductases, a group of enzymes that constitute a major detoxifying pathway for HNE and related reactive aldehydes in human brain. We have determined the regional, cellular, and class distribution in human brain of the 4 major aldo-keto oxidoreductases that detoxify HNE: aldehyde dehydrogenase (ALDH); aldose reductase; aldehyde reductase; and alcohol dehydrogenase (ADH). Of these 4 enzymes, only ALDH and aldose reductase were expressed in cerebral cortex, hippocampus, basal ganglia, and midbrain; all 4 enzymes were present in cerebellum. In cerebrum and hippocampus, aldose reductase was localized to pyramidal neurons and mitochondrial class 2 ALDH was localized to glia and senile plaques. ALDH, but not aldose reductase, activity was significantly increased in temporal cortex from patients with AD compared to age-matched controls. These results suggest that in brain regions involved in AD, neurons and glia utilize different mechanisms to detoxify HNE, and that increased ALDH activity is a protective response of cerebral cortex to AD.
INTRODUCTION
4-Hydroxy-trans-2-nonenal (HNE) and related carbonyls, such as acrolein, are reactive intermediates generated from oxidative damage to polyunsaturated fatty acids (1, 2) . These ␣,␤ unsaturated aldehydes are electrophilic compounds that alkylate nucleophilic groups located on proteins, nucleic acids, and aminophospholipids (2) (3) (4) (5) . HNE-protein adduct and acrolein-protein adduct immunoreactivity, brain tissue levels of HNE, and cerebrospinal fluid levels of HNE are elevated in patients with Alzheimer disease (AD), Parkinson disease, and amyotrophic lateral sclerosis (6) (7) (8) (9) (10) (11) (12) (13) . Several in vitro and cell culture experiments have suggested that these reactive carbonyls may contribute to neurodegeneration by a number of mechanisms (14) (15) (16) (17) (18) (19) . HNE directly inhibits respiration at the level of complex III activity in isolated rat brain mitochondria (14) . Disruption of the cytoskeleton and direct modification of tubulin has been demonstrated in Neuro2A cells (15) . Cell culture experiments using primary hippocampal neurons demonstrate that HNE treatment depletes cellular glutathione, induces de novo lipid peroxidation, and inhibits mitochondrial function (19) . Synaptosomal studies indicate that HNE forms adducts upon and inhibits the glutamate transporter (17) . Alterations in these parameters are associated with neurodegenerative disease. Indeed, based on experiments using neuronal cultures, HNE has been proposed as one of the principal effectors of A␤ peptide-mediated neurodegeneration (20, 21) .
Analogous to superoxide dismutases, glutathione peroxidases, and catalase that detoxify reactive oxygen species, cytoprotective enzymes have evolved that catalyze the detoxification of reactive aldehydes. Two major detoxification pathways exist for HNE and acrolein. First is the glutathione pathway in which the electrophile is conjugated to glutathione, primarily through the action of glutathione S-transferases (GSTs) (22, 23) . Decreased GST activity has been reported in diseased regions of AD brain, a result that may be interpreted as suggesting limited biological significance of reactive carbonyls in AD, or as suggesting that AD brain has diminished protection from the neurotoxic effects of HNE and related aldehydes (24) . The other major metabolic pathway for aldehyde detoxification is oxidation or reduction of the aldehyde to its corresponding acid or alcohol, respectively, by aldo-keto oxidoreductases (25, 26) .
Aldehyde oxidation to the corresponding acid is catalyzed by aldehyde dehydrogenases (ALDH; EC 1.2.1.3). Class 1 and class 2 ALDH are NADϩ requiring enzymes that have a low K M (Ͻ10 M) towards propionaldehyde and that metabolize HNE to its corresponding acid, 4-hydroxy-(2)-nonenoic acid (25, 27) . Class 1 ALDH is located within the cytosol and has a pI of 5.1; class 2 ALDH is localized to mitochondria and has a pI of 4.9. In contrast, class 3 ALDH utilizes either NAD ϩ or NADP ϩ as cofactors in vitro, has a high K M (Ͼ2 mM), and does not metabolize HNE (28) . ALDH activity and expression have been determined in human brain where only class 2 ALDH mRNA has been detected (27, (29) (30) (31) . However, the regional and cellular localization of ALDH in human brain, and the activity of this enzyme in AD brain is not known. The potential importance of ALDH activity in AD was underscored recently by the report of an increased risk for AD in Japanese patients who inherited the ALDH2*2 allele, which encodes a dominant negative inactive form of class 2 ALDH (32) .
Aldehyde reduction to the corresponding alcohol is catalyzed by members of the aldo-keto reductase superfamily (AKR), aldehyde reductase (AKR1A1; EC 1.1.1.2), and aldose reductase (AKR1B1; EC 1.1.1.21), as well as by 3 classes of alcohol dehydrogenases (ADH EC 1.1.1.1) (26, [33] [34] [35] . Aldehyde reductase is approximately 3-fold more active towards HNE than aldose reductase although both metabolize acrolein at the same rate (26). One immunohistochemical survey of human tissue for aldose reductase described immunoreactivity with ''neuronal cells and neuroglial elements'' in cerebrum and with all components of cerebellum except internal granule cells (36) . Class 1 and class 2 ADH catalyze reduction of HNE; however, class 3 ADH, a glutathione-dependent formaldehyde dehydrogenase, does not metabolize HNE (33) . In human brain, immunoreactivity for class 3 ADH is present in cerebellar Purkinje cells and some pyramidal neurons of the cerebral cortex and hippocampus; however, class 1 ADH shows only vascular immunoreactivity and immunohistochemical analysis for class 2 ADH has not been reported (37) . We are not aware of any study that has investigated activity, localization, or genetic associations for these reductases in AD.
The compelling evidence from in vitro and human tissue studies for a pathogenic role for HNE and related aldehydes in AD and the recent genetic association between an inactive isoform of ALDH and AD underscore the potential importance of these cytoprotective enzymes in brain. Therefore, we have determined the regional, cellular, and class distribution in human brain of the 4 major aldoketo oxidoreductases that detoxify HNE: ALDH, aldose reductase, aldehyde reductase, and ADH. In addition, we tested the hypothesis that altered cellular localization and increased activities of aldo-keto oxidoreductases may occur as a protective response to reactive aldehyde generation in AD.
MATERIALS AND METHODS

Human Brain Tissue
Following appropriate consent, all individuals included in this study had postmortem examinations as part of rapid autopsy programs at the University of Kentucky Alzheimer's Disease Research Center or Vanderbilt University Medical Center. No patient had a postmortem interval (PMI) greater than 3 hours (h). All tissue was kept frozen at Ϫ80ЊC until used. All AD patients were diagnosed with probable AD during life and were shown by neuropathological examination to meet the criteria for definite AD (38) . Controls were age-and gender-matched individuals without clinical evidence of dementia or other neurological disease. Each control subject had annual neuropsychological testing with all test scores in the normal range.
Antibodies and Purified Proteins
Anti-ALDH antiserum raised against class 2 enzyme and purified class 1 and class 2 ALDH proteins were the kind gift of Dr. Henry Weiner (Purdue University). Anti-aldose reductase and anti-aldehyde reductase antisera were the kind gift of Dr. John Hayes (University of Dundee) (26). Anti-ADH antiserum recognizing class 1 and class 2 ADH, but not class 3 enzyme, and purified ADH ␤ 1 protein were the kind gift of Dr. Thomas Hurley (Indiana University Medical Center). Recombinant human aldose reductase and aldehyde reductase were expressed in E. coli using a pET15b vector encoding human aldose reductase N-terminally fused to 6 histidine residues and a thrombin cleavage site as described by O'Connor et al (26). Expression was induced and protein purified as previously described using Ni-NTA chelating agarose (Qiagen, Valencia, CA) (26). Protein purity was analyzed by SDS-PAGE. Protein was dialyzed extensively into PBS (125 mM NaCl, 10 mM NaH 2 
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The table lists immunoreactivity for these 2 enzymes in neuron soma, glia soma, or neuropil as absent (Ϫ), present (ϩ), or strongly present (ϩϩ).
was measured with Protein Assay Reagent (BioRad, Hercules, CA) using bovine serum albumin as the standard.
SDS-PAGE
Human brain tissue (frontal cortex or hippocampus) was homogenized in a 10-fold volume of buffer (50 mM hepes, pH 7.0, 4ЊC) containing PMSF 5 g/ml. The homogenate was boiled for 10 min and passed through a 28-gauge needle to shear the DNA. Samples were diluted to 0.5 mg/ml in SDS-PAGE sample buffer containing 50 mM dithiothreitol and boiled for 5 min. Electrophoresis was performed on 8%-16% polyacrylamide gradient gels (BioRad) at 160 V for 50 min.
Isoelectric Focusing
Isoelectrofocusing (IEF) gel electrophoresis of sample homogenates was performed using vertical polyacrylamide IEF gels (pH 5-8 or pH 3-10) from BioRad. Homogenates were diluted 4:1 with 50% glycerol containing bromophenol blue. Samples were electrophoresed at 4ЊC with starting voltage of 100 V for 1 h, followed by 250 V for 1 h, and finally 500 V for 30 min.
Immunoblotting
Following gel electrophoresis (either SDS-PAGE or IEF), proteins were transferred to Sequiblot PVDF membranes (BioRad) at 70 V for 70 min. Membranes were blocked with 3% nonfat dry milk in tris-buffered saline (TBS) for 3 h at room temperature. Antisera were diluted (ALDH 1:20,000; ADH 1:1,000, AKR1A1 1:5,000, AKR1B1 1:5,000) in blocking solution containing 0.2% (vol/vol) tween 20. Membranes were incubated with the antibodies for 16 h at 4ЊC. The membranes were washed with TBS containing 0.2% (vol/vol) tween 20 (twice for 5 min) followed by TBS (twice for 5 min). Horseradish peroxidase conjugated anti-rabbit secondary antibody (1:2,500, Southern Biotechnology, Birmingham, AL) was incubated with the blots for 2 h at room temperature and washed as above. Blots were developed using chemiluminescent substrate (NEN Life Science Products, Boston, MA) with Kodak BioMax film or a chromogenic substrate (TMB-Blotting; Pierce, Rockford, Il).
Immunohistochemistry
Immunohistochemistry was performed as previously described on 8-m sections from tissue blocks that had been fixed in formalin and embedded in paraffin using the Trilogy antigen retrieval system (Cell Marque, Austin, TX) (6) . Primary antisera to ALDH, aldose reductase, aldehyde reductase, and ADH were used at 1:1,000, 1:200, 1:200, and 1:250 dilutions, respectively. Antisera against CD68 (Dako, Carpinteria, CA), GFAP (Dako), and A␤ peptide (Zymed, South San Francisco, CA) were used at a 1:100, 1:1,000, and 1:25 dilutions, respectively. Secondary antibody was conjugated to horseradish peroxidase and diaminobenzidine was used as chromogen substrate. For immunostaining against 2 antigens, 1 secondary antibody was conjugated to alkaline phosphatase with Fast Red used as a substrate. Controls included omission of primary antiserum or competition of primary antiserum with excess purified antigen.
Determination of PMI Effects
Ten-week-old, male, CB57/Bl6 mice (Jackson Labs) were killed by exposure to carbon dioxide. Brains were removed at Fig. 2. Localization of ALDH, aldose reductase, aldehyde reductase, and ADH in human brain. ALDH immunoreactivity is noted in glia (black arrows) of the frontal cortex (A), dopaminergic neurons (C) of the substantia nigra (the white arrow denotes neuromelanin), and Bergmann glia (noted by black arrows) of the cerebellum (E). Diffuse, punctate staining was generally observed in the neuropil but was concentrated in glial soma and surrounding blood vessels (A, E). Aldose reductase immunoreactivity was localized to neuronal soma in the frontal cortex (B), dopaminergic neurons (D) of the substantia nigra (white arrows denote neuromelanin, black arrows denote positive immunostaining), and cerebellar Purkinje neurons and internal granule neurons (F). Aldehyde reductase immunoreactivity (G) and ADH immunoreactivity (H) were localized to blood cells in the hippocampus (black arrows denote immunonegative pyramidal neurons). Magnifications: A, B, D-H, ϫ400; C, ϫ1,000.
time of death, or 3 or 7 h postmortem and then frozen and stored at Ϫ80ЊC until used.
Aldehyde Oxidoreductase Assays
Frozen samples were weighed and homogenized in a 10-fold volume (weight/volume) of ice-cold isolation buffer (20 mM NaH 2 PO 4 , pH 7.0 at 4ЊC) containing 0.1% Triton X-100, 1 mM diethylenetriaminepentaacetic acid (DTPA), and 50 M butylated hydroxytoluene (BHT). Samples were centrifuged at 14,000 g for 10 min at 4ЊC to pellet cellular debris and the supernatant retained. Aliquots of the supernatant were frozen for subsequent immunochemical assays. ALDH activity was assayed by measuring the increase in fluorescence of NADH (excitation ϭ 340 nm, emission ϭ 445 nm) in a fluorescent microplate reader (SpectraMax Gemini, Molecular Devices, Sunnyvale, CA) (39). Assay buffer was 0.1 M NaH 2 PO 4 , pH 7.4, and assays were performed at 37ЊC. Buffer (240 l), supernatant (50 l), and NAD ϩ (1 mM, Sigma, St. Louis, MO) were combined and monitored for 10 min until a baseline rate of fluorescence was reached. To measure low K M ALDH activity (either class 1 or class 2 ALDH), propionaldehyde (70 M; Sigma) was added and the reaction monitored for 10 min. Low K M activity was taken to be the propionaldehyde-stimulated rate of fluorescent increase minus the baseline rate with added NAD ϩ alone. 1.2 mM propionaldehyde was then added to measure remaining ALDH activity termed high K M activity (40) . High K M activity was determined by subtracting the total 70 M propionaldehyde-stimulated rate from the 1.2 mM propionaldehyde-stimulated rate. Protein concentrations of supernatant were determined, and the ALDH activity calculated as nmol NADH formed/min/mg protein. Assays of each sample were performed in quadruplicate and mean rates determined.
Aldose reductase activity was measured in brain homogenates with glyceraldehyde (10 mM) and NADPH (0.1 mM) as substrates using a modified procedure of Song et al in which the formation of NADP ϩ is measured fluorometrically (41, 42) . The use of xylose as a more selective substrate for aldose reductase was not compatible with the fluorometric determination of NADP ϩ (43) . Assays were performed at 37ЊC. Samples (25 l) were added to 75 l assay buffer (50 mM KPO 4 , pH 6.6, containing 0.2 M LiSO 4 ) and incubated for 5 min. NADPH was added and the samples incubated for an additional 1 min. The reaction was started by the addition of glyceraldehyde and proceeded for 10 min. The reaction was stopped by the addition of 25 l of 2N HCl. 6N NaOH (750 l) containing 10 mM, imidazole was added and the samples heated at 60ЊC for 10 min and then cooled on ice. 200 l of this reaction was loaded per well in 96 well plates. Fluorescence was measured using 370 nm excitation and 445 nm emission. Samples were analyzed with and without ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate (EBPC, 1 M), a highly selective inhibitor of aldose reductase (44, 45) . EBPC was the kind gift of Pfizer Central Research (Groton, CT). Aldose reductase activity was taken as the EBPC-inhibited rate of fluorescence formation and expressed as nmol NADPϩ formed/min/mg protein (45) . Assays on each sample were performed in triplicate and mean rates were determined.
Statistical Analyses
Statistical analyses were performed using Prism software (GraphPad, Inc., San Diego, CA) Student t-test and analysis of variance were used as needed.
RESULTS
Immunoblots were performed to determine antisera specificity in homogenates of human cerebral cortex and hippocampus; immunoreactive bands of identical molecular weight were obtained from both sites. Antiserum raised against human class 2 ALDH recognized purified class 1 and class 2 ALDH, but not class 3 (Fig. 1A) . The 1 immunoreactive band comigrated with purified class 2 ALDH protein (Fig. 1B) . Antiserum against human aldose reductase recognized a band that comigrated with purified human aldose reductase (Fig. 1C) (26, 46) . A less intense, higher molecular weight aldose reductase-immunoreactive band also was detected; this band has been noted previously by others (26, 46). Competition with purified human aldose reductase ablated signal for both bands. A single immunoreactive band that comigrated with purified aldehyde reductase was present (Fig. 1D ). An immunoreactive band was highlighted by anti-ADH antiserum (Fig. 1E ) and this was blocked by competition with purified ADH ␤ 1 (not shown).
These antisera were used to localize the aldo-keto oxidoreductases within several regions of brain from control individuals. Omission of primary antiserum was used as negative control in all experiments. In addition, competition with excess purified protein was performed with class 2 ALDH and recombinant aldose reductase; in all cases competition ablated tissue immunoreactivity. Whereas anti-ADH antiserum was reactive with only discrete sites in brain (see below), inclusion of ADH ␤ 1 as competitor led to blanket immunoreactivity with all tissue elements, presumably secondary to nonspecific binding of ADH ␤ 1 to tissue; this precluded competition experiments in tissue for ADH immunoreactivity. Thus, although ADH antiserum reacted with a single band of appropriate mass on immunoblots of cerebral cortex and hippocampus and this was fully competed by ADH ␤ 1 , inability to perform competition experiments in tissue limits certainty about the specificity of this antiserum in tissue.
Immunoreactivity for ALDH and aldose reductase was concentrated in gray matter of cerebral cortex, hippocampus, basal ganglia, midbrain, and cerebellum with only scattered immunoreactive cells in white matter. Choroid plexus epithelium was immunoreactive for both ALDH and aldose reductase; however, neither enzyme was localized to blood vessel walls or leptomeninges. The distribution of ALDH and aldose reductase immunoreactivities in cerebral cortex, hippocampus, basal ganglia, midbrain, and cerebellum is summarized in the Table. In the cerebral cortex and hippocampus, glial cell bodies but not neuron cell bodies displayed punctate ALDH immunoreactivity (Figs. 2A, 5A,  B) . In addition, neuropil showed diffusely scattered, punctate ALDH immunoreactivity. Double label immunohistochemistry for GFAP or CD68 plus ALDH showed that the vast majority of ALDH-immunoreactive glia were astrocytes although some ALDH glial immunoreactivity colocalized with CD68, a microglial marker (not shown) (47, 48) . In contrast, aldose reductase immunoreactivity in the cerebral cortex and hippocampus was localized exclusively to pyramidal neuron cell bodies where it showed diffuse cytoplasmic staining (Fig. 3B) . Unlike the intensity of ALDH immunoreactivity that was relatively uniform among cells, pyramidal neurons in the cerebral cortex and hippocampus showed variability in the intensity of aldose reductase immunoreactivity, although virtually every neuron showed at least some immunoreactivity. This variation in the intensity of aldose reductase immunoreactivity was most striking in the hippocampus where pyramidal neurons in CA1 were conspicuously and consistently less immunoreactive than pyramidal neurons in the other hippocampal sectors (Fig. 3) .
Punctate glial soma and neuropil immunoreactivity for ALDH was maintained in basal ganglia, midbrain, and cerebellum; however, neurons in the subthalamic nucleus, globus pallidus, substantia nigra, and periaqueductal gray matter also showed ALDH immunoreactivity (Fig. 2C,  E) . This is not surprising, at least for dopaminergic neurons in the substantia nigra, where ALDH is known to catalyze the terminal step in the synthesis of 3,4-dihydroxyphenylacetic acid (DOPAC). Similar to cerebral cortex and hippocampus, aldose reductase did not localize to glial soma in the basal ganglia, midbrain, or cerebellum; however, neuron cell bodies showed diffuse cytoplasmic immunoreactivity in all of these brain regions (Fig. 2D, F) .
Aldehyde reductase was localized to the cytoplasm of cerebellar internal granule cells, choroid plexus epithelium, and blood cells within vessels; however, there was no immunoreactivity with brain parenchyma in the cerebral cortex, basal ganglia, or midbrain (Fig. 2G) . ADH was localized to glia in the cerebellum, vascular smooth muscle cells within brain and in the sub-arachnoid space, blood and blood cells within small vessels, and to choroid plexus epithelium (Fig. 2H ). There was no nuclear staining with any of the 4 antiserum.
These data indicated that of the 4 aldo-keto oxidoreductases that will detoxify HNE and related aldehydes, only ALDH and aldose reductase were present in cerebral cortex and hippocampus, the regions of brain involved by AD. Isoelectric focusing followed by immunoblotting with anti-ALDH was used to distinguish class 1 ALDH from class 2 ALDH. Only class 2 ALDH was identified in homogenates of superior and middle temporal gyri (SMTG) from controls (n ϭ 6, representative blot shown in Fig. 4) . These results are in accord with northern blot data demonstrating only class 2 ALDH mRNA in human brain (30) . 7 . Low K M ALDH activity but not aldose reductase activity is elevated in AD. A: ALDH activity was measured using homogenates of the superior middle temporal gyrus from 6 controls and 4 AD patients. B: Total reductase and aldose reductase activity was measured using the identical samples as for the ALDH activity measurements. Aldose reductase activity is defined as the rate of reductase activity inhibited by 1 M EBPC. * ϭ p Ͻ 0.05 using the Student t-test.
Next, we tested the hypothesis that alterations in localization, class distribution, or activity of ALDH or aldose reductase may occur in the cerebral cortex and hippocampus of AD patients. ALDH immunoreactive processes were present in senile plaques in cerebral cortex and hippocampus, likely a result of reactive glia within these structures (Fig. 5A, B) . Plaque ALDH immunoreactivity colocalized mostly with GFAP but also some with CD68 (not shown). Indeed, ALDH immunoreactivity in AD cerebrum was virtually identical to GFAP immunoreactivity. Double label immunohistochemistry for ALDH and A␤ peptides showed that most plaques possessed ALDH-immunoreactive processes (not shown). ALDH immunoreactivity still was undetectable in cerebral cortical and hippocampal neurons in AD patients. No alteration in the distribution or apparent intensity of aldose reductase was observed in cerebral cortex or hippocampus of AD patients.
Class distribution of ALDH in SMTG of AD patients (n ϭ 4) was identical to controls; only class 2 ALDH was observed (Fig. 4) . Although there is only 1 class of aldose reductase in brain, its pI varies with the thiol redox status of the enzyme (46) . Therefore, the pI of aldose reductase in SMTG was determined in AD patients and controls (Fig.  6) ; there was no difference in the pI for aldose reductase between these 2 groups.
Finally, we determined the activity of ALDH and aldose reductase in cerebral cortex from controls and AD patients. In order to determine the effect of PMI on enzyme activity, low K M (class 1 and class 2) and high K M ALDH were determined in mouse brain with PMI ϭ 0, 3, or 7 h. Low K M activity was not significantly altered between 0 h (0.218 Ϯ 0.021 nmol/min/mg; n ϭ 4) and 3 h (0.243 Ϯ 0.029 nmol/min/mg; n ϭ 4). At 7 h postmortem, low K M ALDH activity was significantly decreased versus 0 and 3 h PMI (0.136 Ϯ 0.013 nmol/min/mg; n ϭ 4; p Ͻ 0.05). High K M activity was not altered at 3 or 7 h. Based on these findings, all human tissue used in activity studies had PMI Ͻ 3 h. Low K M but not high K M ALDH activity was increased in homogenates of SMTG from AD patients compared to controls (p Ͻ 0.05, Fig. 7A ). Combined with the earlier results from isoelectric focusing gels, these data indicate that class 2 ALDH activity is increased in temporal cortex of AD patients. Reductase activity was determined in the same in SMTG samples as used for ALDH activity. Aldose reductase activity was defined as fraction of total reductase activity that was blocked by EBPC, a potent and highly selective inhibitor of aldose reductase. In contrast to low K M ALDH activity, there was no significant difference in total reductase or aldose reductase activity between AD patients and controls (Fig. 7B) .
DISCUSSION
Oxidative stress generates numerous reactive intermediates, and when these exceed the anti-oxidant defenses of the organism, oxidative damage ensues. Thus, increased levels of oxidative stress or decreased anti-oxidant defenses may underlie the regionally increased oxidative damage to brain that is a feature of AD (49, 50) . Several detoxification pathways for reactive intermediates produced from oxidative stress have evolved to protect against oxidative damage, these include DNA repair enzymes, superoxide dismutases, catalase, glutathione-dependent enzyme systems, and aldo-keto oxidoreductases (51) . All of these except aldo-keto oxidoreductases already have been studied with respect to AD (24, (52) (53) (54) (55) (56) . This is a potentially important gap in our knowledge because aldo-keto oxidoreductases along with GSTs are the major detoxifying systems for reactive aldehydes such as HNE and acrolein in other organs, and these reactive aldehydes are proposed to be important in AD progression. If this proposal is correct, then aldo-keto oxidoreductase or GST activities in diseased regions of AD brain might be expected to increase in response to reactive aldehyde generation. Contrary to this expectation, others have recently shown that GST activity is decreased in diseased regions of AD brain compared to controls (24) .
In the present study, we examined the cellular expression and activities of the major oxidoreductases that metabolize HNE and related aldehydes in brain. We found that mitochondrial class 2 ALDH is the major form in human cerebral cortex and that expression of this enzyme was limited to glia in cerebral cortex and hippocampus. Expression of aldose reductase was complimentary to ALDH; aldose reductase was limited to pyramidal neuron cytoplasm in cerebral cortex and hippocampus. Moreover, pyramidal neuron immunoreactivity for aldose reductase was not uniform. For example, pyramidal neurons in hippocampal sector CA1, a region with heightened vulnerability to a number of injuries, were less immunoreactive for aldose reductase than were pyramidal neurons in other hippocampal sectors. Aldehyde reductase and ADH were not expressed in brain parenchyma of cerebral cortex or hippocampus. Class 2 ALDH immunoreactivity was prominent in senile plaques and low K M ALDH activity was significantly increased in temporal cortex from AD patients compared with controls. Neither the distribution nor activity of cerebral cortical aldose reductase was different between AD patients and controls. In contrast to GST activity, induction of ALDH activity and expression in senile plaques are consistent with the hypothesis that reactive aldehyde generation is a significant stress to brain in AD.
HNE-protein adducts, acrolein-protein adducts, and protein carbonyls accumulate in AD largely in cerebral cortical and hippocampal neuron cytoplasm with less accumulation in glial cytoplasm (6, 8, 9, 13, 57) . Two possible explanations for the preferential accumulation of aldehyde-modified proteins in neurons are either greater lipid peroxidation in neurons than in glia, or less detoxification of reactive aldehydes in neurons than in glia. The former possibility is supported by recent work from our laboratory; diseased regions of AD brain have significantly greater neuroprostanes (free radical oxidation products from docosahexaenoic acid that is concentrated in neurons) than isoprostanes (free radical oxidation products from arachidonic acid that is evenly distributed among brain cells) (58) . The fact that aldose reductase has a k cat for HNE that is over 30 times greater than class 2 ALDH does not support the second possibility that neurons are less able to detoxify reactive aldehydes (25, 35) . However, our results showed that only ALDH activity was increased in AD brain. Moreover, class 2 ALDH compartmentalization to mitochondria may enhance overall protective function since the majority of oxygen free radicals are thought to derive from mitochondria. Clearly, the issue of relative protection from reactive aldehydes in neurons and glia in vivo is complex and cannot be resolved from these data; nevertheless, our results do show that cerebral cortical and hippocampal neuronal mitochondria lack a major detoxification pathway for reactive aldehydes.
Similar to what we observed with ALDH, increased glial expression of enzymes to detoxify reactive intermediates or pro-oxidants has been observed previously in AD brain. Manganese superoxide dismutase (Mn-SOD) is localized to mitochondria and catalyzes the detoxification of superoxide (54) . Heme oxygenase-1 (HO-1) catalyzes the conversion of heme, a pro-oxidant, to compounds with anti-oxidant activity (55, 56) . In AD, both Mn-SOD and HO-1 are prominently expressed in reactive astrocytes and both enzymes are localized to senile plaques (54) (55) (56) . In contrast to ALDH, Mn-SOD and HO-1 are expressed in pyramidal neurons in controls, and HO-1 also is associated with neurofibrillary pathology in AD (56) .
Whether elevations in ALDH expression are a direct result of oxidative stress or exposure to reactive aldehydes such as HNE is not known and must be addressed using model systems such as in vitro cell culture. Comparison of ALDH activity with levels of unreacted HNE from postmortem tissue is confounded by the fact that elevations in tissue ALDH activity may lead to a decrease in the tissue levels of HNE through metabolism of HNE to 4-hydroxy-2-nonenoate. Indeed, previous work has shown that tissue levels of unreacted HNE are not significantly elevated in the SMTG of patients with AD even though other nonmetabolized markers of lipid peroxidation are elevated in the SMTG in AD (59, 60) .
The results from our experiments demonstrated that the cellular distribution of the 4 aldo-keto oxidoreductases that metabolize HNE varies among regions of human brain. Especially interesting was ALDH, which was exclusively localized to glia in the cerebral cortex and hippocampus but was present in neurons of some basal ganglia and substantia nigra. Also intriguing was the finding that the cerebellum expressed all 4 of the oxidoreductases investigated. The potential relationship between these differences in distribution of aldo-keto oxidoreductases and the susceptibility of these brain regions to diseases involving oxidative stress remains to be established. While our results agree with the earlier immunohistochemical report on ADH in human brain, our results do not agree with the only previous report on the distribution of aldose reductase in human brain (36) . The reasons for these differences are not known; however, it should be noted that this earlier study did not insure specificity of antiserum by performing Western blots on brain homogenates or by competition experiments in tissue sections.
Our results suggest that increased class 2 ALDH activity in cerebral cortex and hippocampus of AD patients is a protective response to increased reactive aldehyde generation in this disease. The significance of class 2 ALDH activity to the progression of AD is further underscored by a recent association between inheritance of a dominant negative inactive allele for class 2 ALDH and increased risk for AD (32) . It is noteworthy that ALDH activity can be reduced by a number of dietary and environmental factors in addition to inheritance (32, 61) . In combination, these data suggest that mitochondrial ALDH is an important means by which cerebral cortex and hippocampus attempt to limit damage in AD, and may represent a focus where genetic and environmental factors may influence the initiation or progression of AD.
